Abstract 467P
Background
Lung cancer is a serious problem and one of the most common cancer diseases worldwide. Many studies were shown that free-circulating mtDNA levels are increased in the serum/plasma of patients with various malignancies. Here we analysed mtDNA levels in the plasma of patients with NSCLC compared to the health individuals.
Methods
68 patients with NSCLC and 59 healthy individuals were recruited for this study. A quantitative analysis of the free-circulating mtDNA was conducted using the qPCR. To create a standard curve, the purified PCR product of the 490 bp mtDNA fragment was used. The DNA concentration determined using the PicoGreen dsDNA Quantification Kit. The copy number of the free-circulating mtDNA was calculated according to the protocol of Applied Biosystems.
Results
The levels of free-circulating mtDNA in patients with NSCLC were found in range from 2.7x1010 to 6,51x1014 with a mean value 3,04x1013 copies/μL. In plasma samples of healthy subjects the levels of mtDNA copies were found to range from 6,0x109 to 1,73x1013 with a mean value 7,46x1011. Thus, the levels of free-circulating mtDNA in patients with NSCLC were higher in 6.6 times than in those of healthy subjects (P < 0.05).
Conclusions
Results of this study suggest that high free-circulating mtDNA copies number is a promising marker for diagnosis and prediction of non-small cell lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Ministry of Education and Science of the Republic of Kazakhstan (grant no. 1258/GF4).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract